BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 15772076)

  • 1. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
    Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
    J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
    Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
    Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
    Inoki K; Li Y; Xu T; Guan KL
    Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the unique biological function of small GTPase RHEB.
    Yu Y; Li S; Xu X; Li Y; Guan K; Arnold E; Ding J
    J Biol Chem; 2005 Apr; 280(17):17093-100. PubMed ID: 15728574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
    Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
    Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of rapamycin.
    Kimball SR; Jefferson LS
    Curr Opin Clin Nutr Metab Care; 2004 Jan; 7(1):39-44. PubMed ID: 15090902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
    Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
    J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
    Li Y; Inoki K; Guan KL
    Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
    Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
    Castro AF; Rebhun JF; Clark GJ; Quilliam LA
    J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced energy stress regulates mRNA translation and cell growth.
    Liu L; Cash TP; Jones RG; Keith B; Thompson CB; Simon MC
    Mol Cell; 2006 Feb; 21(4):521-31. PubMed ID: 16483933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
    Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
    Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheb binds and regulates the mTOR kinase.
    Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J
    Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
    Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
    FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
    Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
    J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation.
    Ravitz MJ; Chen L; Lynch M; Schmidt EV
    Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis.
    Kimball SR; Do AND; Kutzler L; Cavener DR; Jefferson LS
    J Biol Chem; 2008 Feb; 283(6):3465-3475. PubMed ID: 18070882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.